The adverse effects in the control group were as follows: one patient developed a case of anemia; one developed both leukopenia and neutropenia; five experienced creatine kinase increases; three developed elevated AST; two developed elevated ALT; and one subject developed a Grade 3 transaminitis (ALT elevation), which improved spontaneously. This evidence concerns the gene GPT and anemia.